Semaglutide vs. tirzepatide — which is better for weight loss?

The only head-to-head obesity trial, SURMOUNT-5, settled the efficacy question: tirzepatide produced ≈20.2% average weight loss versus ≈13.7% for semaglutide 2.4 mg over 72 weeks — roughly 47% more relative loss, with more participants crossing every milestone (≥15%, ≥20%, ≥25% lost). So why isn’t the answer simply “tirzepatide for everyone”? The case for semaglutide: - Cardiovascular outcomes proof. SELECT showed semaglutide 2.4 mg cut major cardiac events by 20% in people with CV disease and overweight/obesity. Tirzepatide’s CV outcomes trial is still maturing — most experts expect benefit, but semaglutide has it proven. - Longer real-world record at weight-management doses, plus an oral option (Rybelsus) and the largest body of safety data. - Cost and access: often cheaper compounded, sometimes better covered, and its generic horizon is nearer. The case for tirzepatide: - More weight loss for the same effort — decisive if your goal demands ≥20%. - In trials, comparable or slightly lower rates of nausea/vomiting at equivalent weight loss; many patients who struggled on semaglutide tolerate it better. - An approved sleep-apnea indication. The honest tiebreakers: individual response varies enormously — some people respond dramatically to semaglutide and modestly to tirzepatide, and vice versa; nobody can predict which you’ll be. Insurance formularies often make the decision for you. And switching later is routine, so the first pick is rarely final.